Abivax SA

ABVX

Company Profile

  • Business description

    Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

  • Contact

    7-11 boulevard Haussmann
    Paris75009
    FRA

    T: +33 153830963

    https://www.abivax.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    69

Stocks News & Analysis

stocks

Here’s how to value a share

Our best resources to help investors determine the value of a share.
stocks

How to avoid dividend disaster

Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks

GyG punished by market after solid earnings

Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,273.2038.10-0.41%
CAC 407,969.6931.400.40%
DAX 4024,363.0969.750.29%
Dow JONES (US)45,631.74846.241.89%
FTSE 1009,321.4012.200.13%
HKSE25,691.54352.401.39%
NASDAQ21,496.54396.221.88%
Nikkei 22542,909.09275.800.65%
NZX 50 Index13,128.4585.690.66%
S&P 5006,466.9196.741.52%
S&P/ASX 2009,002.4041.70-0.46%
SSE Composite Index3,848.6722.910.60%

Market Movers